Search Results - "SEREMETIS, S"

Results from a large multinational clinical trial (guardian™1) using prophylactic treatment with turoctocog alfa in adolescent and adult patients with severe haemophilia A: safety and efficacy by Lentz, S. R., Misgav, M., Ozelo, M., Šalek, S. Z., Veljkovic, D., Recht, M., Cerqueira, M., Tiede, A., Brand, B., Mancuso, M. E., Seremetis, S., Lindblom, A., Martinowitz, U.

“…Summary Recombinant factor VIII (rFVIII) products provide a safe and efficacious replacement therapy for prophylaxis and treatment of bleeding episodes in…”
Get full text

Treatment of acquired haemophilia with recombinant activated FVII: a critical appraisal by SUMNER, M. J., GELDZILER, B. D., PEDERSEN, M., SEREMETIS, S.

“…Acquired haemophilia is a rare bleeding disorder usually caused by the spontaneous formation of inhibitory antibodies to coagulation FVIII. The disease occurs…”
Get full text

Results from a large multinational clinical trial (guardian™3) using prophylactic treatment with turoctocog alfa in paediatric patients with severe haemophilia A: safety, efficacy and pharmacokinetics by Kulkarni, R., Karim, F. A., Glamocanin, S., Janic, D., Vdovin, V., Ozelo, M., Rageliene, L., Carboni, E., Laguna, P., Dobaczewski, G., Seremetis, S., Lindblom, A., Santagostino, E.

“…Summary Recombinant factor VIII (rFVIII) products provide a safe and efficacious replacement therapy for prophylaxis and treatment of bleeding episodes in…”
Get full text

Perioperative management of haemophilia B: A critical appraisal of the evidence and current practices by Neufeld, E. J., Solimeno, L., Quon, D., Walsh, C., Seremetis, S., Cooper, D., Iyer, N. N., Hoxer, C. S., Giangrande, P.

“…Background While there is substantial literature addressing the principles of general management of haemophilia, literature on perioperative management of…”
Get full text

Recombinant activated factor VII in approved indications: Update on safety by Neufeld, E. J., Négrier, C., Benchikh el Fegoun, S., Cooper, D. L., Rojas‐Rios, A., Seremetis, S.

Get full text

Re: Discordant pair analysis of rFVIIa and pd-aPCC response by COOPER, D. L., SEREMETIS, S., CARR JR, M. E.

Get full text

Comparative thrombotic event incidence after infusion of recombinant factor VIIa vs. factor VIII inhibitor bypass activity—a rebuttal by SALLAH, S., ISAKSEN, M., SEREMETIS, S., PAYNE ROJKJAER, L.

Get full text

Modern treatment of haemophilia by BERNTORP, E, BOULYJENKOV, V, SEREMETIS, S, BRETTLER, D, CHANDY, M, JONES, P, LEE, C, LUSHER, J, MANNUCCI, P, PEAK, I, RICKARD, K

“…Many rapid advances have been made in the diagnosis and therapy of haemophilia. Nevertheless, the condition still poses problems and challenges (e.g., joint…”
Get full text

Cost minimization model for treatment of minor bleeding episodes in inhibitor patients - methodological issues by SEREMETIS, S., JOSHI, A. V., ASMUSSEN, M.

Get full text

Human recombinant DNA-derived antihaemophilic factor (factor VIII) in the treatment of haemophilia A: conclusions of a 5-year study of home therapy by SEREMETIS, LUSHER, ABILDGAARD, KASPER, ALLRED, HURST

“…Fifty‐eight previously treated haemophilic subjects were treated exclusively with the recombinant FVIII (rFVIII‐KOGENATE®) produced by Bayer Corporation…”
Get full text

Internalization of Human Immunodeficiency Virus Type I and Other Retroviruses by Megakaryocytes and Platelets by Zucker-Franklin, D., Seremetis, S., Zheng, Z.Y.

“…Direct infection of megakaryocytes and platelets by human immunodeficiency virus type I (HIV-I) or other retroviruses has not been demonstrated. To determine…”
Get full text

Monoclate-P--hemofil-M study by Seremetis, S

Get full text

Growth- and Tumor-Promoting Effects of Deregulated BCL2 in Human B-Lymphoblastoid Cells by Nunez, Gabriel, Seto, Masao, Seremetis, Stephanie, Ferrero, Dario, Grignan, Francesco, Korsmeyer, Stanley J., Dalla-Favera, Riccardo

“…Human follicular B-cell lymphomas possess a t(14;18) that translocates a putative protooncogene, BCL2, into the immunoglobulin heavy chain locus. The normal…”
Get full text

Sex-related differences in hemostasis and thrombosis by Seremetis, S V

“…Disorders of thrombosis and hemostasis represent both diagnostic and therapeutic challenges for the clinician, in part because of sex-based differences in…”
Get more information

Biochemistry and expression of myelomonocytic antigens by Goyert, SM, Ferrero, EM, Seremetis, SV, Winchester, RJ, Silver, J, Mattison, AC

“…Six monoclonal antibodies (MAb) which react with myelomonocytic cells representing various stages of differentiation, and which precipitate six different cell…”
Get full text

The clinical use of factor VIIa in the treatment of factor VIII inhibitor patients by Seremetis, S V

Get more information

Desmopressin nasal spray for hemophilia A and type I von Willebrand disease by Seremetis, S V, Aledort, L M

Get full text

Three-year randomised study of high-purity or intermediate-purity factor VIII concentrates in symptom-free HIV-seropositive haemophiliacs: effects on immune status by Seremetis, S V, Aledort, L M, Bergman, G E, Bona, R, Bray, G, Brettler, D, Eyster, M E, Kessler, C, Lau, T S, Lusher, J

“…The availability of monoclonal-antibody-purified factor VIII (FVIII) concentrates allows us to test the hypothesis, based on in vitro observations, that their…”
Get more information

High frequency of clonal immunoglobulin or T cell receptor gene rearrangements in acute myelogenous leukemia expressing terminal deoxyribonucleotidyltransferase by SEREMETIS, S. V, PELICCI, P.-G, TABILIO, A, UBRIACO, A, GRIGNANI, F, CUTTNER, J, WINCHESTER, R. J, KNOWLES, D. M. II, DALLA-FAVERA, R

“…Ig and T cell receptor rearrangements have been used as irreversible markers of lineage and clonality in the study of B- and T-lymphoid populations. We have…”
Get full text

Violence and women: case presentation and discussion by Seremetis, S V

Get more information